Capivasertib plus abiraterone combination lands indication for PTEN-deficient tum ...

A research team at Kanazawa University, led by Professor Atsushi Mizokami, Associate Professor Koji Izumi and Specially ...

A previous trial involving patients with metastatic prostate cancer that was resistant to androgen pathway modulation (formerly referred to as castration-resistant) showed that adding talazoparib ...

The statistics are sobering and undeniable — African American men develop prostate cancer at twice the rate of white men and are more likely to die from the disease. This reality makes understanding ...

Active surveillance is a standard approach for managing men with low‑risk prostate cancer to help delay or avoid treatment, but a significant number of patients eventually experience disease ...

AstraZeneca’s TRUQAP® (capivasertib) in combination with abiraterone and prednisone has been approved in the US as the first and only targeted treatment for adult patients with PTEN-deficient ...

Detailed results from pivotal TALAPRO-3 study presented at ASCO 2026 and published in The New England Journal of Medicine ...

Symptoms linked to urinary or sexual health often carry an element of embarrassment, making men less likely to discuss them ...

Talazoparib plus enzalutamide met the primary endpoint in TALAPRO-2, lowering radiographic progression or death risk by 37% versus enzalutamide, with median rPFS not reached. Efficacy signals extended ...

There are around 46,000 new cases of prostate cancer each year in England and Wales, with 13% of these cases showing signs of ...